Independent thinking for complex markets and current events
Pfizer beats out Novo with $10B agreement to buy Metsera After a chaotic and fierce bidding clash that only burst out into public view a little more than a week ago, Pfizer has prevailed in its pursuit of obesity biotech Metsera. https://www.fiercebiotech.com/biotech/pfizer-beats-out-novo-10b-agreement-buy-metsera Bourla claims his new products are moving at the “speed of light.” Full… …
https://invezz.com/news/2025/09/22/pfizer-close-to-acquiring-metsera-for-7-3b-targeting-breakthrough-obesity-drug/ Pfizer nears $7.3B deal to acquire Metsera, targeting next-gen obesity treatments. MET-097i shows 11.3% weight loss in trials and offers monthly dosing. Acquisition positions Pfizer against Novo Nordisk and Eli Lilly in obesity market. Pfizer is making a bold move in the pharmaceutical world by closing in on a $7.3 billion deal to acquire …